| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780737 | Gynecologic Oncology | 2018 | 7 Pages |
Abstract
In a prospective setting ASRGL1 validates as a strong prognostic biomarker in endometrial carcinoma. Loss of ASRGL1 is associated with aggressive disease and poor survival, and is demonstrated for the first time to have independent prognostic value in the entire endometrial carcinoma patient population.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Tina Fonnes, Hege F. Berg, Therese Bredholt, Per-Henrik D. Edqvist, Kristina Sortland, Anna Berg, Helga B. Salvesen, Lars A. Akslen, Henrica M.J. Werner, Jone Trovik, Ingvild L. Tangen, Camilla Krakstad,